Long-term progression-free survival in a patient with advanced non-small-cell lung cancer treated with low-dose gefitinib and traditional herbal medicine: A case report

RATIONALE: Gefitinib is a first-line palliative chemotherapy drug used to treat advanced non-small-cell lung cancer (NSCLC) in patients who have an epidermal growth factor receptor (EGFR) mutation. However, approximately two-thirds of NSCLC patients with EGFR-tyrosine kinase inhibitor experience der...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Beom-Joon, Kim, Kwan-Il, Choi, Cheong-Woon, Kim, Jong Yeol, Lee, Jun-Hwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
3800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870175/
https://www.ncbi.nlm.nih.gov/pubmed/33592873
http://dx.doi.org/10.1097/MD.0000000000024292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870175/
https://www.ncbi.nlm.nih.gov/pubmed/33592873
http://dx.doi.org/10.1097/MD.0000000000024292

Ejemplares similares